Owen O’Connor Provides an In-depth Analysis of the New Paradigm in T-cell Lymphoma Treatment | CSCO 2025

Owen O’Connor Provides an In-depth Analysis of the New Paradigm in T-cell Lymphoma Treatment | CSCO 2025

2025.09.23
The 2025 Chinese Society of Clinical Oncology (CSCO) Annual Meeting was grandly held in the golden autumn season, gathering top experts from the global field of oncology. In the lymphoma session, the renowned American scholar, Professor Owen O'Connor, delivered a splendid presentation on the topic "REASONS FOR OPTIMISM IN TREATING THE T-CELL MALIGNANCIES: A BIOLOGICAL BASIS COMES INTO FOCUS." He systematically reviewed the historical challenges in the treatment of T-cell lymphoma and emphatically elaborated on why epigenetic targeting will be the key to turning the tide, pointing to a hopeful new path for the future treatment of this disease.
Professor Qing Zou: Advancing Comprehensive Therapy and “Full-Course Management” Systems for Urologic Malignancies

Professor Qing Zou: Advancing Comprehensive Therapy and “Full-Course Management” Systems for Urologic Malignancies

2025.09.18
In recent years, the management of urologic malignancies—including kidney cancer and bladder cancer—has been moving toward a new era of comprehensive care, innovative treatments, multidisciplinary collaboration (MDT), and multi-technology integration. The goal is to build a “full-course management” system that maximizes clinical benefit for patients by combining advances from across specialties. At the 2025 Pujiang Uro-Oncology Conference, Professor Qing Zou of Jiangsu Cancer Hospital shared the latest developments in the diagnosis and treatment of representative urologic tumors such as kidney cancer and non–muscle-invasive bladder cancer (NMIBC). He also discussed the implementation of innovative technologies, MDT collaboration, and the experience of building a full-course management system.